PDE5A and type 2 diabetes mellitus: Comparatively, short half-life PDE5 inhibitors (sildenafil, avanafil) had no decrease in HbA1c or a statistically significant increase (p = 0.03) in HbA1c when considering a subset most representative of type 2 diabetes, thereby confirming the conclusion from earlier meta-analyses.